>> Nausea and vomiting was the dose-limiting factor of this study in all cohorts. As an illustration, the patients in the once a week cohort were only able to attain, on average, approximately 35% of the target dosing levels… "To ultimately achieve this objective [a best in class drug], we must effectively deal with the nausea observed in this trial. We are confident we can do so, based on the guidance coming out of this trial and tangible steps already undertaken." <<
-- As you may recall (#msg-2841010), I was not as impressed with the interim results –including the relatively high dropout rate-- as some other posters here. I’m still in “show me” mode on this product.
Market Data 
Markets 
AI
